Advances in Tardive Dyskinesia: A Review of Recent Literature


In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement


Related Videos
© 2023 MJH Life Sciences

All rights reserved.